The Kim laboratory is focused on the Immunological components of the tumor microenvironment under the context of translating the findings towards clinical trials. We have characterized the adaptive immune resistance mechanisms of PD-L1 on the tumor cells that have resulted in a clinical impetus towards combination of cancer vaccines, adjuvants, radiation, and/or targeted oncological agents with immune checkpoint inhibitors. We are focused on the STING pathway, neoantigen development, as well as other targetable immune checkpoint inhibitors and co-activators such as NKG2A, NKG2D, KIRs, TIGIT.
Associate Professor of Otolaryngology, Chair in Laryngeal, Head and Neck Research, Otolaryngology
602 Oxford House1313 21st Avenue SouthNashville, TN 37232-4480